News
KMDA
6.07
+2.71%
0.16
Weekly Report: what happened at KMDA last week (0331-0404)?
Weekly Report · 6d ago
Weekly Report: what happened at KMDA last week (0324-0328)?
Weekly Report · 03/31 09:13
Kamada declares $0.20 dividend
Seeking Alpha · 03/24 12:02
Kamada Announces Tax Ruling on Special Cash Dividend
TipRanks · 03/24 11:27
Kamada provides update on withholding tax procedures on special cash dividend
TipRanks · 03/24 11:26
Weekly Report: what happened at KMDA last week (0317-0321)?
Weekly Report · 03/24 09:11
Kamada Price Target Announced at $15.00/Share by Benchmark
Dow Jones · 03/21 13:53
Benchmark Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $15
Benzinga · 03/21 13:42
FedEx downgraded, Adobe upgraded: Wall Street’s top analyst calls
TipRanks · 03/21 13:37
Kamada initiated with a Buy at Benchmark
TipRanks · 03/21 10:36
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 03/17 12:58
Weekly Report: what happened at KMDA last week (0310-0314)?
Weekly Report · 03/17 09:12
Weekly Report: what happened at KMDA last week (0303-0307)?
Weekly Report · 03/10 09:12
Kamada Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 03/06 12:24
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga · 03/06 12:14
Kamada: A Growth-Oriented Investment with Strong Financials and Strategic Expansion Plans
TipRanks · 03/06 11:36
Kamada Ltd’s Growth at Risk: Manufacturing Capacity and Expansion Challenges Loom Large
TipRanks · 03/06 06:02
Kamada Ltd. Reports Record 2024 Financial Results
TipRanks · 03/06 04:03
Kamada Ltd Reports Record 2024 Earnings and Positive 2025 Outlook
TipRanks · 03/06 00:19
Kamada declares $0.20 dividend
Seeking Alpha · 03/05 12:30
More
Webull provides a variety of real-time KMDA stock news. You can receive the latest news about Kamada Ltd through multiple platforms. This information may help you make smarter investment decisions.
About KMDA
More
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.